Synmosa Biopharma (4114) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Synmosa Biopharma (4114) has a cash flow conversion efficiency ratio of 0.018x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$185.72 Million ≈ $5.85 Million USD) by net assets (NT$10.10 Billion ≈ $318.18 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Synmosa Biopharma market cap and net worth for the company's overall valuation and market capitalisation.
Synmosa Biopharma - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Synmosa Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Synmosa Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synmosa Biopharma ranked by their cash flow conversion efficiency. Explore Synmosa Biopharma (4114) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ChoiceOne Financial Services Inc
NASDAQ:COFS
|
0.030x |
|
Sligro Food Group NV
AS:SLIGR
|
-0.090x |
|
Guangdong Zhengye Technology Co Ltd
SHE:300410
|
-0.059x |
|
Visco Vision Inc.
TW:6782
|
0.061x |
|
YeaShin International Development Co Ltd
TWO:5213
|
-0.145x |
|
Logan Energy Corp
V:LGN
|
0.019x |
|
Optotech Corp
TW:2340
|
-0.010x |
|
Lake Materials Co. Ltd.
KQ:281740
|
0.006x |
Annual Cash Flow Conversion Efficiency for Synmosa Biopharma (2015–2025)
The table below shows the annual cash flow conversion efficiency of Synmosa Biopharma from 2015 to 2025. View Synmosa Biopharma stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$10.10 Billion ≈ $318.18 Million |
NT$411.57 Million ≈ $12.97 Million |
0.041x | -56.15% |
| 2024-12-31 | NT$8.40 Billion ≈ $264.61 Million |
NT$780.62 Million ≈ $24.59 Million |
0.093x | +47.08% |
| 2023-12-31 | NT$8.10 Billion ≈ $255.22 Million |
NT$511.93 Million ≈ $16.13 Million |
0.063x | -33.33% |
| 2022-12-31 | NT$6.65 Billion ≈ $209.47 Million |
NT$630.25 Million ≈ $19.86 Million |
0.095x | +30.05% |
| 2021-12-31 | NT$6.10 Billion ≈ $192.04 Million |
NT$444.29 Million ≈ $14.00 Million |
0.073x | +70.61% |
| 2020-12-31 | NT$5.95 Billion ≈ $187.60 Million |
NT$254.40 Million ≈ $8.02 Million |
0.043x | +558.15% |
| 2019-12-31 | NT$4.81 Billion ≈ $151.63 Million |
NT$-44.88 Million ≈ $-1.41 Million |
-0.009x | -361.48% |
| 2018-12-31 | NT$4.49 Billion ≈ $141.31 Million |
NT$16.00 Million ≈ $503.96K |
0.004x | +372.28% |
| 2017-12-31 | NT$3.97 Billion ≈ $124.93 Million |
NT$-5.19 Million ≈ $-163.64K |
-0.001x | -102.41% |
| 2016-12-31 | NT$4.35 Billion ≈ $137.14 Million |
NT$236.48 Million ≈ $7.45 Million |
0.054x | +593.84% |
| 2015-12-31 | NT$3.01 Billion ≈ $94.96 Million |
NT$23.60 Million ≈ $743.59K |
0.008x | -- |
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, gr… Read more